Reportlinker Adds Biopharmaceuticals Market Trends & Competition

Jun 10, 2010, 11:48 ET from Reportlinker

NEW YORK, June 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biopharmaceuticals Market Trends & Competition

http://www.reportlinker.com/p0204912/Biopharmaceuticals-Market-Trends--Competition.html

Today's pharmaceutical industry is shifting toward biopharmaceuticals at a drastic speed. In 2009, sales of biopharmaceutical drugs accounted for 13% of the total sales of pharmaceuticals. And today, biopharmaceuticals account for 25% of all pharmaceuticals in the development pipeline. We expect that biopharmaceuticals will maintain double digit growth in the years to come, and form a rapidly growing market.

Eying this dramatically expanding market, companies are expanding biopharmaceutical discovery and development, and becoming active in M&A activities including involvement in bio-ventures. As a result, competition is becoming increasingly fierce.

In this study, we describe and report on the current state and future trends of biopharmaceutical drugs in the global market, including:

1. Market Overview

2. Worldwide Biopharmaceutical Drug Market Trends, 2009-2013

3. US Biopharmaceutical Drug Market Trends

?US Sales of Biopharmaceutical Drugs by Disease Category, 2009-2013

?New Drug Market Entries by Disease Category, 2009-2013

???Manufacturers' Share by Disease Category

4. Worldwide Innovative Biopharmaceutical Dug Development by Disease Category

?New Drug Pipelines by Disease Category

?New Players to Enter the Market by Disease Category

?Beyond the Pipeline: Hot Categories and Players' Product Development Strategy

5. Worldwide Biopharmaceutical Drug Strategies by Major Company

???Major Alliances, M&A and IP

?Worldwide Biopharmaceutical Drug Strategies by Major Company

?Worldwide Biopharmaceutical Drug R&D by Major Company

?Patents, Business Development & Challenges for Worldwide Biopharmaceutical Drug by Major Company

6.? Important Findings and Suggestions for Business Opportunities

Disease Categories:

Alzheimer's disease, Anemia, Arthritis, Asthma, Cancer, CAPS, Diabetes, Fabry disease, Gaucher's disease, Growth hormone deficiency, Hepatitis C, HIV, Lupus, Multiple sclerosis, Neutropenia, Osteoporosis, Parkinson's disease, Transplant rejection, Ulcerative colitis, Vaccines, Other conditions.

Major Companies:

Abbott Laboratories, AMBiS, Amgen, Bayer, Biogen Idec, Bristol-Myers Squibb,

Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Elan, Eli Lilly, Genetech,

Genzyme, GlaxoSmithKline, Hayashi Kasei Co., Ltd., Human Genome Sciences, Johnson & Johnson, Katakura Industries Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck,

Merck Serono, Neosilk Co., Ltd., Novartis, Novo Nordisk, Oriental Yeast Co., Ltd. Pfizer, Regeneron, Roche, Sanofi-Aventis, Shionogi & Co., Ltd., Shire, Swedish Orphan Biovitrum, Takeda Pharmaceutical Co., Ltd., Toyobo Co., Ltd., UCB Pharma

Table of Contents

1. Market Overview

1.1 Worldwide Biopharmaceutical Drug Market

Table 1.1: Worldwide Biopharmaceutical Drug vs. Medical Drug

Table 1.2: Worldwide Biopharmaceutical Drug vs. Medical Drug by Region

1.2 Noteworthy Biopharmaceutical Drug

1.3 Worldwide Biopharmaceutical Drug R&D

Table 1.3: Biopharmaceutical Drug R&D Expenditure by Region

1.4 Noteworthy Biopharmaceutical Drug Company for R&D expenditure

Table 1.4 Top 10 Company R&D Expenditure for Biopharmaceutical Drug

2. Worldwide Biopharmaceutical Drug Market Trends, 2009 – 2013

2.1 Worldwide Total Biopharmaceutical Drug Market by Company, 2009

Table 2.1: Global Sales of Biopharmaceutical Drugs by 25 Companies, 2009

Figure 2.1: Worldwide Market Share of top 15 Manufacturers of Biopharmaceutical Drugs, 2009

2.2 Worldwide Total Biopharmaceutical Drug Market by Disease Category, 2009 - 2013

Table 2.2: Worldwide Sales of All Biopharmaceuticals by 20 Categories, 2009 - 2013

2.3 Worldwide Total Biopharmaceutical Drug Market by Branded Product, 2009 - 2013

Table 2.3: Worldwide Sales of All Biopharmaceuticals by 109 Branded Products, 2009 – 2013

2.4 Worldwide Total Biopharmaceutical Drug Market by Region, 2009 - 2013

Table 2.5: Worldwide Sales of All Biopharmaceuticals by World Region, 2009 - 2013

3. US Biopharmaceutical Drug Market, 2009 - 2013

3.1 Overview

3.1.1 Industry & Market Current Trends

3.1.2 Industry Spending for Biopharmaceutical R&D

3.1.3 US Prescription Volume for Biopharmaceuticals

3.2 US Sales of Biopharmaceutical Drugs

3.2.1 US Sales of Biopharmaceutical Drug by Disease Category

Table 3.1: US Sales of All Biopharmaceuticals by 20 Categories, 2009 - 2013

3.2.2 US Sales of Biopharmaceutical Drugs by Company

Table 3.2: US Sales of Biopharmaceutical Drugs by 23 Companies, 2009

Figure 3.1: US Market Share of 15 Manufacturers of Biopharmaceutical Drugs, 2009

3.2.3 US Sales of Biopharmaceutical Drugs by 20 Disease Categories

Common Research Item:

?US Sales of Biopharmaceutical Drugs, 2009

?US Market Share of Biopharmaceutical Players, 2009

?US Sales of Biopharmaceutical Drugs, 2009-2013

?US Sales Growth of Biopharmaceutical Companies, 2009-2013

3.2.3.1 Alzheimer's Disease

3.2.3.2 Anemia

3.2.3.3 Arthritis

3.2.3.4 Asthma

3.2.3.5 Cancer

3.2.3.6 Cryopyrin-Associated Periodic Syndrome (CAPS)

3.2.3.7 Diabetes

3.2.3.8 Fabry Disease

3.2.3.9 Gaucher's Disease

3.2.3.10 Growth Hormone Deficiency

3.2.3.11 Hepatitis C

3.2.3.12 HIV

3.2.3.13 Lupus

3.2.3.14 Multiple Sclerosis

3.2.3.15 Neutropenia

3.2.3.16 Osteoporosis

3.2.3.17 Parkinson's Disease

3.2.3.18 Transplant Rejection

3.2.3.19 Ulcerative Colitis

3.2.3.20 Vaccines

3.2.3.21 Other Conditions

3.3 Issues and Sales Drivers

4. Worldwide Innovative Biopharmaceutical Drug Development by Disease Categories

4.1 New Drug Pipelines and Players for Future Growth by 20 disease Categories

Table 4.1: At Glance

4.1.1 Alzheimer's Disease – 4.1.21 Other Conditions

4.2 New Players to Enter the Market by 20 Disease Categories

4.2.1 Alzheimer's Disease – 4.2.21 Other Conditions

4.3 Beyond the Pipeline: Hot Categories and Players' Product Development Strategy

5. Worldwide Biopharmaceutical Strategy by Major Company

5.1 Major Alliances, M&A and IP

Table 5.1: Major Biotech Alliances, 2009

5.2 Worldwide Biopharmaceutical Drug Strategies by Company

5.2.1 Abbott Laboratories

5.2.2 Amgen

5.2.3 Bayer

5.2.4 Biogen Idec

5.2.5 Bristol-Myers Squibb

5.2.6 Chugai Pharmaceutical Co., Ltd.

5.2.7 Daiichi Sankyo Co. Ltd.

5.2.8 Elan

5.2.9 Eli Lilly

5.2.10 Genetech

5.2.11 Genzyme

5.2.12 GlaxoSmithKline

5.2.13 Human Genome Sciences

5.2.14 Johnson & Johnson

5.2.15 Kyowa Hakko Kirin Co., Ltd.

5.2.16 Merck

5.2.17 Merck Serono

5.2.18 Novartis

5.2.19 Novo Nordisk

5.2.20 Pfizer

5.2.21 Regeneron

5.2.22 Roche

5.2.23 Sanofi-Aventis

5.2.24 Shire

5.2.25 Swedish Orphan Biovitrum

5.2.26 Takeda Pharmaceutical Co., Ltd.

5.2.27 UCB

5. 3 Worldwide Biopharmaceutical Drug R&D by Major Company

5.3.1 Abbott Laboratories – 5.3.34 UCB Pharma (Total 34 Companies)

5.4 Patents, Business Development & Challenges for Worldwide Biopharmaceutical Drug Major Company

5.4.1 Abbott Laboratories – 5.4.28 UCB (Total 28 Companies)

6. Important Findings and Suggestions/Recommendations for Business Opportunities

7. Appendix

7.1 Selected Companies Mentioned in this Report

Table 7.1: Major Biopharmaceutical Companies

To order this report:

Biopharmaceutical Industry: Biopharmaceuticals Market Trends & Competition

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com